Tuesday, February 23, 2010
HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex™ on 25 February 2010.
The company obtained European Certification for OvPlex™ paving the way to market and sell the product within the European community.
Take home message: The emergence of new targeted anticancer therapies promises more efficient and less toxic therapies. Generally, they are well tolerated, toxicities are commonly mild to moderate and can be handled rapidly. However, if most of these adverse events are manageable, life threatening and fatal complications can still occur.
Take home message: Although not life-threatening, toxicity of sorafenib can severely impact the physical, psychological and social well-being of patients. The management of this unusual toxicity highlights the particular need of new pluridisciplinarities linking oncologist, cardiologist and dermatologist
Importance of the field: Antiretroviral therapy exhibits significant potential to alter the metabolism of other medications. Warfarin is widely used for the management of clotting disorders and is prone to drug–drug interactions that can result in subtherapeutic anticoagulation or over-anticoagulation. (warfarin, HIV, antiretroviral, drug interaction, protease inhibitor (PI), non-nucleoside reverse-transcriptase inhibitor (NNRTI), cytochrome P450 (CYP450), CYP2C9)
CLINICAL TRIALS IN CANADA Optimizing Patient Participation in a Global Market April 29 - 30, 2010 Montréal
Note: the conference fees
"For preventing the onset of CIPN, the committee recommended further clinical testing of intravenous calcium and magnesium, which reduced CIPN symptoms by approximately half compared with a placebo in one trial
Note: prophylatic surgeries??
"Dr Zorbas said the figure had remained "fairly stable" for years and the lower level could represent the start of a new plateau, though the reason for the small drop was not yet clear......."The number of women diagnosed with ovarian cancer is expected to increase, and that's because the population is increasing and we have an increasingly ageing population," Dr Zorbas told AAP."
Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer.
CONCLUSIONS: Self-selection of women seeking risk-reducing salpingo-oophorectomy, changes in lifestyle after surgery, and survival bias may explain that the women who underwent risk-reducing salpingo-oophorectomy had a more favorable coronary heart disease risk profile compared with the controls. Longitudinal studies are needed to further clarify the associations observed in this cross-sectional study.
Note: mucinous is not specific to ovarian cancer but found in other tumour sites and without expert pathology can be confused with mucinous gastrointestinal tumours
"At a National Cancer Institute-sponsored workshop it was proposed that the borderline category of ovarian intestinal-type mucinous tumors (OInMTs) could be eliminated if the apparent benign behavior of these tumors could be confirmed..."
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell ad
Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study CONCLUSIONS: A phase III randomized trial is required to elucidate the effectiveness of CPT-P combination chemotherapy for CCC
Patients and Online Communities - The advancement and popularity of patient communities online is an international phenomenon. We’ll be examining communities in different cultures, languages and context, and see what impact they have on care delivery in different countries–and what the internationalization of information means for patients and doctors.
The patient perspective from:
- Roberto Ascione, PagineMediche.it Italy
- Gilles Frydman, ACOR america
- Ben Heywood, PatientsLikeMe america
- Neil Bacon, iWantGreatCare UK
- Christian Angele, imedo Germany